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Abstract
Background: High-intensity focused ultrasound (HIFU) ablation is a non-invasive treatment for hepato-
cellular carcinoma (HCC). At present, data on the treatment's long-term outcome are limited. This study
analysed the survival outcome of HIFU ablation for HCCs smaller than 3 cm.
Patients and methods: Forty-seven patients with HCCs smaller than 3 cm received HIFU treatment
between October 2006 and September 2010. Fifty-nine patients who received percutaneous radiofre-
quency ablation (RFA) were selected for comparison. The two groups of patients were compared in terms
of pre-operative variables and survival.
Results: More patients in the HIFU group patients had Child–Pugh B cirrhosis (34% versus 8.5%; P =
0.001). The 1- and 3-year overall survival rates of patients whose tumours were completely ablated in the
HIFU group compared with the RFA group were 97.4% versus 94.6% and 81.2% versus 79.8%,
respectively (P = 0.530). The corresponding 1- and 3-year disease-free survival rates were 63.6% versus
62.4% and 25.9% versus 34.1% (P = 0.683).
Conclusions: HIFU ablation is a safe and effective method for small HCCs. It can achieve survival
outcomes comparable to those of percutaneous RFA and thus serves as a good alternative ablation
treatment for patients with cirrhosis.
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Introduction
Hepatocellular carcinoma (HCC) is a common cancer and the
third most common cause of cancer mortality. The incidence of
HCC is particularly high in Asia where hepatitis B virus infection
is endemic. Hepatitis-B-related cirrhosis and HCC make a bad
combination for patients as treatment options are relatively lim-
ited.1 Hepatectomy and liver transplantation are widely accepted
as good treatment choices for most patients with small HCCs.
However, local ablation therapy is a very good alternative for
patients who do not want or cannot tolerate a major surgical
procedure.2 Among the different methods of ablation for HCC,
radiofrequency ablation (RFA) is relatively popular because of its
simplicity and repeatability.
Since 2005, RFA has been recommended as a treatment option
in the practice guidelines issued by the American Association for
the Study of Liver Disease.3 Percutaneous RFA has been shown to
provide complete ablation results and good survival outcomes,
especially in treating small HCCs. However, when lesions are
located at difficult sites, such as the liver dome or sites near the
liver capsule, percutaneous RFA will probably result in a residual
tumour. Moreover, patients with gross ascites which is a sign of
decompensation of cirrhosis may not be suitable for this treat-
ment modality.
High-intensity focused ultrasound (HIFU) ablation is a rela-
tively new treatment for HCC. Long-term data are still lacking.
HIFU treatment utilizes a unique frequency of the ultrasound
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wave of 0.8 to 3.5 MHz, which can be focused at a distance from
the therapeutic transducer. The accumulated energy at the
focused region causes oscillation of the particles, inducing necro-
sis of the target lesion by elevating the tissue temperature to above
60°C.4,5 As very little collateral damage to the peripheral structure
is made, this treatment modality has been shown to be a safe
procedure in patients even with advanced cirrhosis.6 This study
analysed the results of HIFU ablation and percutaneous RFA in
the treatment of HCCs smaller than 3 cm.
Patients and methods
From October 2006 to September 2010, 1321 patients at Queen
Mary Hospital were diagnosed with HCC, and 457 (34.6%) of
them received surgical intervention. The clinical data were
recorded prospectively. Patients with primary HCCs smaller than
3 cm and first recurrence were included in this study. Patients who
had multiple treatments and patients with extrahepatic disease
were excluded from the study.
HCCwas diagnosed if (i) the AFP is greater than 200 ng/ml and
the radiological appearance of the mass is suggestive of HCC or
(ii) there are typical arterial enhancement patterns with portal
venous wash out in two imaging modalities.3
All patients with HCCs smaller than 3 cm were evaluated for
operability. Their general condition, liver function, tumour status
and tumour location were assessed. As a general guideline, a hepa-
tectomy or open RFA was offered as a first treatment if the
patient’s liver function and physical status were satisfactory and
a liver transplantation was offered if the patient had advanced
cirrhosis rendering a hepatectomy a high-risk procedure.
For patients who preferred a less invasive approach, percutane-
ous RFA was offered if technically feasible as assessed by an expe-
rienced radiologist. HIFU ablation was offered to patients with
poor liver function or decompensated cirrhosis as documented by
(i) the presence of gross ascites, (ii) Child–Pugh B or above and
(iii) tumours located at sites considered difficult for percutaneous
RFA. HIFU ablation was also offered to patients as an alternative
ablation treatment for those who want to avoid needle puncture
from RFA. Transarterial chemoembolization was reserved for
non-ablatable tumours in this series. Patients who received mul-
tiple treatments and crossover treatment with RFA were not
included in this study.
Percutaneous RFA
Percutaneous RFA was performed by an experienced liver surgeon
together with one or two experienced interventional radiologists.
The ablation was performed with ultrasound guidance under
local anaesthesia with light sedation. All RFA treatments were
performed according to a standard protocol, using the cool-tip RF
system (Radionics, Burlington,MA, USA). A single electrode with
a 2- or 3-cm exposed tip was used for tumours smaller than 3 cm
in diameter, whereas a clustered probe consisting of three parallel
electrodes was used for tumours around 3 cm in size.Ablation was
performed with a curative intention, aiming to achieve an ablation
margin of 1 cm. A dose of antibiotic (Augmentin; Beecham Phar-
maceuticals, Brentford, London, UK) was given just before the
operation and oral antibiotics were given for 5 days after the
operation.7,8 to avoid a potential risk of infection.
HIFU ablation
HIFU ablation was performed by the same team of surgeons and
radiologists.We used the JCHIFU system (ChongqingHaifu Tech-
nology, Chongqing, China), which consists of an ultrasound
energy transducer which focuses the ultrasound energy at a 12-cm
focal point. A degassed water circulation unit provides a medium
for ultrasound transmissionoutside the body.Patientswere usually
placed in a right lateral position for right-sided lesions and in a
prone position for left-sided lesions.General anaesthesia allowed a
more comfortable procedure. In addition, interval cessation of
respiratory movement, which was performed by an anaesthesiolo-
gist, facilitated better localization of the HCC during energy trans-
fer. In patients with tumours at the dome of the liver, an artificial
right pleural effusion was induced before treatment. An artificial
pleural effusion is introduced by instilling 600 to 800 ml of warm
saline into the patient’s right thoracic cavity. The saline displaces
the lung parenchyma temporarily and a good acoustic pathway for
the ultrasound energy is formed. With respiratory control, the
tumour can be displaced to a location where HIFU beams can be
properly administered.Grey-scale changes of the ablated sites were
observed during the ablation procedure, indicating the tempera-
ture change inside the target lesion.A dose of antibiotic (Augmen-
tin; Beecham Pharmaceuticals) was given just before the operation
and oral antibiotics were given for 5 days after the operation.5,6
Follow-up
Post-operative blood tests for a complete blood picture, pro-
thrombin time and liver and renal functions were performed rou-
tinely on days 1, 3, 7 and 14, or according to specific clinical
situations. Contrast computed tomography or magnetic reso-
nance imaging was performed 1 month after ablation. Assessment
scans were performed with 3-month intervals during the first 2
years and with 6-month intervals thereafter. Complications were
defined as any deviation from the normal post-operative course.
This definition also takes into account asymptomatic complica-
tions such as arrhythmia and atelectases.9 Complete ablation was
defined as the disappearance of the enhancement pattern of the
lesion as compared with the pre-operative lesion on imaging per-
formed 1month after ablation.Mortality was defined as any death
during the hospital stay or less than 30 days after the intervention.
The location of the liver tumour was described according to the
Brisbane 2000 classification.10
Statistical analysis
Baseline characteristics of patients were expressed as medians
with range. The Mann-Whitney U-test was used to compare con-
tinuous variables, and a chi-squared test was used to compare
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discrete variables. Survival analysis was performed using the time
of disease-free survival versus recurrence of the tumour or death.
Survival curves were computed using the Kaplan–Meier method
and compared between groups using the log-rank test. A P-value
below 0.05 signified statistical significance. All statistical calcula-
tions were made with the SPSS/PC+ computer software (SPSS,
Chicago, IL, USA).
Results
Forty-seven patients received HIFU ablation as a curative treat-
ment and 59 patients received percutaneous RFA. Patients were
enrolled to HIFU treatment in this study as a result of the follow-
ing reasons: (i) 27 (57.4%) patients had failed RFA screening by a
radiologist owing to either poor visualization of lesions or tech-
nical difficulties; (ii) 6 patients (12.8%) had decompensated liver
cirrhosis evidenced by the presence of gross ascites; (iii) 5 patients
(10.6%) had a platelet count lower than 50 ¥ 109/l; (iv) 15 patients
(31.9%) had tumours located close to the diaphragm; (v) 16
patients (34%) had Child–Pugh B cirrhosis; and (vi) 10 patients
(21.3%) preferred a totally non-invasive treatment modality.
In the HIFU group, 47 patients were treated with HIFU ablation
and ablated 52 tumours. The details of patients’ characteristics are
listed in Table 1. Sixteen patients (34%) in the HIFU group and
five patients (8.5%) in the RFA group had Child–Pugh B cirrhosis
(P = 0.001). The two groups showed no difference in terms of the
international normalized ratio, platelet count, and serum levels of
total bilirubin, creatinine, albumin and alpha-fetoprotein. In the
HIFU group, more lesions (55.6%) were located at sections 7 and
8. In the RFA group, fewer tumours (38.4%) were located at the
same sections (P = 0.028). The details of tumours’ characteristics
are listed in Table 2.
Ten patients (21.3%) in the HIFU group developed post-
operative complications. Two of them developed a pneumothorax
after the introduction of an artificial pleural effusion which
required chest tube insertion. One patient had third-degree skin
burn and required surgical debridement. The other patients had
relatively minor complications. Five patients (8.5%) in the RFA
group developed post-operative complications. Two of them
developed a pleural effusion requiring tapping. One patient devel-
oped liver abscess and required percutaneous drainage. One
patient developed oesophageal variceal bleeding owing to decom-
pensation of cirrhosis and required endoscopic haemostasis. The
remaining patient had only a mild wound infection. The details of
the complications are listed in Table 3. When serious complica-
tions (Clavein-Dindo grade IIIA or above) were considered, the
two groups showed no difference.
In the HIFU group, the 1-year overall survival was 97.4% and
the 3-year overall survival was 81.2%. In the RFA group, the
corresponding rates were 94.6% and 79.8% (P = 0.53) (Fig. 1). In
the HIFU group, the 1-year disease-free survival was 63.6% and
the 3-year disease-free survival was 25.9%. In the RFA group, the
corresponding rates were 62.4% and 34.1% (P = 0.683) (Fig. 2).
Discussion
In recent years, there has been much development in HCC-
treating technology and devices, and numerous trials on targeted
therapy have been carried out.11–17 Nevertheless, the general guide-
lines for the treatment algorithm for HCC have been formulated
in actual clinical practice. For HCC patients who do not have
cirrhosis, surgical resection is undoubtedly the treatment of
choice with best survival benefits. On the other hand, the treat-
Table 1 Patient characteristics
HIFU ablation (n = 47) Percutaneous RFA (n = 59) P
Age (years) 62 (34–84) 60 (23–83) 0.095
Male/female 36:11 43:16 0.663
Hepatitis B virus infection 42 (79.2%) 46 (80.7%) 0.849
Hepatitis C virus infection 9 (17%) 10 (17.2%) 0.971
Ascites
Absent 41 (87.2%) 57 (96.6%) 0.148
Present 6 (12.8%) 2 (3.4%)
Child–Pugh class
A 31 (66%) 54 (91.5%) 0.001
B 16 (34%) 5 (8.5%)
Total bilirubin (umol/l) 14 (7–50) 13 (4–57) 0.371
Creatinine (umol/l) 86 (44–878) 78 (46–912) 0.281
Albumin (g/l) 39 (24–46) 39 (23–46) 0.388
International normalized ratio 1.0 (0.8–1.5) 1.1 (0.9–1.4) 0.124
Platelet count (1 ¥ 109) 104 (17–268) 98 (34–228) 0.731
Alpha-fetoprotein (ng/ml) 18 (2–937) 16 (2–10050) 0.694
HIFU, high-intensity focused ultrasound; RFA, radiofrequency ablation.
HPB 569
HPB 2013, 15, 567–573 © 2012 International Hepato-Pancreato-Biliary Association
ment of HCC in patients with cirrhosis is an entirely different
story. Patient with HCCs even smaller than 3 cm may not tolerate
a hepatectomy if they have advanced cirrhosis.2,18,19 A large
tumour size, difficult tumour location, poor underlying liver
function, comorbidity etc. can also render a hepatectomy impos-
sible. A liver transplantation may be the only ultimate solution for
patients unsuitable for a hepatectomy.20 The post-transplant sur-
vival rate of patients within the Milan criteria can be higher than
90% in 5 years at experienced centres.21,22 Although the results of
liver transplantations are generally good, the scarcity of liver grafts
makes it impossible to transplant everyone in need.Many patients
on the transplant waiting list end up delisted as their disease
progresses rendering them unsuitable for transplantation. So, in
an ‘intention-to-treat’ analysis, survival of patients receiving
transplantation may not be better than that of patients carefully
selected for other surgical means.23
Table 2 Tumour characteristics and operative outcomes
HIFU ablation (n = 47) Percutaneous RFA (n = 59) P
Tumour size (cm) 1.5 (0.8–2.7) 1.9 (1.0–2.8) 0.006
Tumour number
1 42 (89.4%) 52 (88.1%) 0.668
2 5 (10.6%) 6 (10.2%)
3 0 (0%) 1 (1.7%)
Tumour location
I 0 (0%) 3 (4.8%) 0.029
II 1 (1.9%) 5 (7.7%)
III 6 (11.5%) 3 (4.8%)
IV 3 (5.7%) 8 (12.3%)
V 0 (0%) 8 (12.3%)
VI 12 (23%) 13 (20%)
VII 17 (32.6%) 6 (9.2%)
VIII 13 (25%) 19 (29.2%)
Complete ablation 41 (87.2%) 56 (94.9%) 0.290
Hospital stay (days) 4 (2–18) 6 (1–31) 0.028
HIFU, high-intensity focused ultrasound; RFA, radiofrequency ablation.
Table 3 Treatment-related complications
HIFU ablation Percutaneous RFA P
(n = 47) (n = 59)
Patients with surgical complications 10 (21.3%) 5 (8.5%) 0.06
Moderate subcutaneous swelling 1 0
Pneumothorax 2 0
Skin burn 2 0
Myocardiac infarction 1 0
Ascites without tapping 2 0
Fever 1 0
Mild right chest wall swelling and pain 1 0
Wound infection 0 1
Pleural effusion requiring tapping 0 2
Liver abscess 0 1
Variceal bleeding 0 1
Clavien–Dindo grade IIIA complication 2 (4.3%) 4 (6.8%) 0.892
Clavien–Dindo grade IVA complication 1 (2.1%) 0 (0%) 0.508
Hospital mortality 0 (0%) 0 (0%) 1
HIFU, high-intensity focused ultrasound; RFA, radiofrequency ablation.
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The technique of local ablation provides a bright hope for
patients who have cirrhosis in addition to small HCCs.24 RFA is
now widely practiced for its simplicity and repeatability. The com-
plete ablation rate achieved by RFA ranges from 75% to 96%.25,26
RFA can be performed percutaneously under ultrasound or com-
puted tomography guidance. Patients need only local anaesthesia
with sedation. Although percutaneous RFA has been performed
safely in many patients, patients with advanced cirrhosis may not
tolerate it satisfactorily. Many interventional radiologists opine
that patients with gross ascites should avoid percutaneous RFA
treatment.As documented in one of the studies on RFA treatment,
patients with slightly a raised bilirubin level and hypoalbuminae-
mia are prone to complications after RFA treatment for HCC.7
Initial studies on HIFU were mainly carried out in Mainland
China, but now many other centres have started using HIFU for
the ablation of solid tumours.4,27–30 HIFU is a totally extracorpor-
eal tool that has been shown to be effective in treating various
tumours. HIFU treatment makes use of the unique frequency of
the ultrasound wave of 0.8 MHz, which makes penetration in soft
tissue up to 12 cm deep possible. Ascites inside the peritoneal
cavity not only provides a clear image for the diagnostic ultra-
sound unit, it also serves as a good medium for energy transfer.
The presence of ascites also protects subcutaneous tissue from
being damaged by the focused ultrasound energy.6,31 With HIFU,
poor liver function with ascites is no longer a contraindication to
HCC treatment.6 In the present study, there were more patients
with Child–Pugh B cirrhosis in the HIFU group. This was because
patients with ascites were not considered suitable for other treat-
ments and were included for HIFU therapy. Liver function test
results of patients having received HIFU ablation are not mark-
edly different, which is unlike the case with patients having
received RFA. Patients having received HIFU treatment also have
a relatively shorter hospital stay as frequent liver function moni-
toring is not required as collateral damage to the normal liver
tissue is minimal.
The needleless feature of HIFU treatment makes it unique
among all ablation therapies. As HCC is a vascular tumour, RFA
needle placement can cause torrential bleeding.32 Although minor
tumour bleeding or rupture can be controlled by the thermal
ablation at the end of the treatment, patients may suffer transient
hypotension or develop complications; closer monitoring at a
hospital is required. In addition, the insertion of an ablation
needle into a tumour can produce a theoretic threat of tumour
dissemination, particularly if the lesion is near major vessels.32,33
The use of HIFU may reduce these potential problems.
This study included patients with primary HCC because
outcome analysis of HIFU and percutaneous RFA provided
important clinical information. In addition, patients with first
recurrent HCC were included because RFA was considered a
popular and effective treatment option amongst surgeons for
recurrent HCC.34 Haemostasis could be a problematic issue for
open procedures such as adhesiolysis and hepatectomy particu-
larly in patients with cirrhosis and a low platelet count. Percuta-
neous RFA and HIFU treatments were considered less invasive
measures for this targeted group of patients. Although HCC
patients with multiple recurrence and cross-over treatment were
not uncommon, they were not included in this study for compari-
son. The outcome would be difficult to interpret if the analysis
included patients receiving different treatments modalities.
The feasibility of percutaneous RFA is sometimes limited by
tumour location. A location near the liver dome at section 7 or
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Figure 1 Comparison of overall survival
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Figure 2 Comparison of disease-free survival
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section 8 is a contraindication to percutaneous RFA because of
potential damage to the diaphragm. On the other hand, HIFU
energy can be targeted at lesions even in difficult positions, like
those close to the diaphragm or the heart.35 After introduction of
an artificial pleural effusion, the saline inside the thoracic cavity
also acts as a protection cushion preventing damage to the dia-
phragm and surrounding soft tissue. Unlike RFA energy which is
usually transferred to the lesion in continuous cycles of 12 min
each, HIFU energy is transferred to the tumour in cycles of
approximately 10 s each with 1-min breaks in between. The
operator has full control on the location, the power of energy
transmitted and the duration of break between cycles of energy
dissipation. This makes HIFU treatment more operator-
dependent; nonetheless, each treatment is tailor-made for the
patient.
There was a case of third-degree burn to the dermis which
required surgical debridement in the early study period. This
occurred in a patients with a lesion located near the subcapsular
region of section 5.When the ultrasound energy was focused near
the rib cage, reflection of the energy might cause accidental soft
tissue oedema and damage to the overlying structure. In addition,
the complication was also contributed to by the early learning
curve effect where the operator was unaware of the soft tissue
oedema demonstrated by the diagnostic ultrasound unit. A high
index of clinical suspicious could prevent a serious complication
during the procedure. Otherwise, complications arising from
HIFU are relatively minor. They are mostly related to soft tissue
oedema or discomfort after the procedure. Symptoms may be
more obvious if the tumour is located close to the subcapsular
region.36 These complications are usually self-limiting. In the
present study, the two groups of patients had similar rates of
serious complications.
There was no survival difference between the two groups. The
complete ablation rate was slightly better in the RFA group but no
significant difference was observed. However, patients with
advanced cirrhosis and considered not suitable for other treat-
ments were included in the HIFU group. More patients were
cured in spite of their background cirrhosis. Long-term survival
data on HIFU treatment will be collected as the follow-up period
lengthens.
In the management of small HCC, we suggest a hepatectomy
for primary HCC with preserved liver function as the first treat-
ment option. RFA should be performed in patients with small but
unresectable HCC where liver transplantation is not an option. A
percutaneous approach should be adopted if technically feasible.
Patients with gross ascites or a tumour located closed to bile duct,
major vessels, gallbladder and diaphragm should not be consid-
ered suitable for percutaneous RFA.HIFU should be considered as
an alternative ablation option for this group of patients. In the
case of recurrent disease, only patients with Child–Pugh class A
cirrhosis and selected patients with Child–Pugh class B cirrhosis
should be considered for re-resection or RFA. The usual indica-
tion for re-resection was a solitary or oligonodular tumour within
a single section of the liver in the presence of a sufficient future
liver remnant. A re-resection should be avoided in the presence of
gross ascites, an indocyanine green retention rate more than 15%
at 15 min and a platelet count lower than 100 ¥ 109/l. Percutane-
ous RFA should be considered when the recurrent tumour is in a
deep-seated location where an anatomical resection will sacrifice a
large amount of functional liver parenchyma. RFA should gener-
ally be avoided in the presence of gross ascites, a platelet count
lower than 50 ¥ 109/l in spite of a platelet transfusion and a
tumour located at difficult position as described above. HIFU
should be considered as an alternative ablation option for this
group of patients.
To conclude, in the treatment of HCCs smaller than 3 cm,
HIFU ablation provides a good oncological outcome, which is
comparable to that of percutaneous RFA. This relatively new
treatment modality can be offered to patients who have a poor
liver function and advanced cirrhosis which render other thera-
pies suboptimal.
Conflicts of interest
None declared.
References
1. Parkin DM, Pisani P, Ferlay J. (1999) Estimates of the worldwide inci-
dence of 25 major cancers in 1990. Int J Cancer 80:827–841.
2. Fan ST. (1999) Surgical therapy of hepatocellular carcinoma in the cir-
rhotic liver. Swiss Surg 5:107–110.
3. Bruix J, Sherman M. (2005) Management of hepatocellular carcinoma.
Hepatology 42:1208–1236.
4. Wu F, Wang ZB, Chen WZ, Wang W, Gui YZ, Zhang M et al. (2004)
Extracorporeal high intensity focused ultrasound ablation in the treatment
of 1038 patients with solid carcinomas in China: an overview. Ultrason
Sonochem 11:149–154.
5. Ng KK, Poon RT, Chan SC, Chok KS, Cheung TT, Tung H et al. (2011)
High-intensity focused ultrasound for hepatocellular carcinoma: a single-
center experience. Ann Surg 253:981–987.
6. Cheung TT, Chu FS, Jenkins CR, Tsang DS, Chok KS, Chan AC et al.
(2012) Tolerance of high-intensity focused ultrasound ablation in patients
with hepatocellular carcinoma. World J Surg 36:2420–2427.
7. Cheung TT, Ng KK, Poon RT, Fan ST. (2009) Tolerance of radiofrequency
ablation by patients of hepatocellular carcinoma. J Hepatobiliary Pan-
creat Surg 16:655–660.
8. Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. (2007) Analysis of
recurrence pattern and its influence on survival outcome after radiofre-
quency ablation of hepatocellular carcinoma. Ann Surg 253:981–987.
9. Dindo D, Demartines N, Clavien PA. (2004) Classification of surgical
complications: a new proposal with evaluation in a cohort of 6336
patients and results of a survey. Ann Surg 240:205–213.
10. Pang YY. (2000) The Brisbane 2000 terminology of liver anatomy and
resections. HPB 2:333–339. HPB (Oxford) 2002; 4: 99-100.
11. Noterdaeme O, Leslie TA, Kennedy JE, Phillips RR, Brady M. (2009) The
use of time to maximum enhancement to indicate areas of ablation
following the treatment of liver tumours with high-intensity focused ultra-
sound. Br J Radiol 82:412–420.
572 HPB
HPB 2013, 15, 567–573 © 2012 International Hepato-Pancreato-Biliary Association
12. Poon RT, Ng KK, Lam CM, Ai V, Yuen J, Fan ST. (2004) Radiofrequency
ablation for subcapsular hepatocellular carcinoma. Ann Surg Oncol
11:281–289.
13. Zhang L, Zhu H, Jin CB, Zhou K, Li KQ, Su HB et al. (2009) High-intensity
focused ultrasound (HIFU): effective and safe therapy for hepatocellular
carcinoma adjacent to major hepatic veins. Eur Radiol 19:437–445.
14. Chapman WC, Debelak JP, Wright PC, Washington MK, Atkinson JB,
Venkatakrishnan A et al. (2000) Hepatic cryoablation, but not radiofre-
quency ablation, results in lung inflammation. Ann Surg 231:752–761.
15. Wong H, Tang YF, Yao TJ, Chiu J, Leung R, Chan P et al. (2011) The
outcomes and safety of single-agent sorafenib in the treatment of elderly
patients with advanced hepatocellular carcinoma (HCC). Oncologist
16:1721–1728.
16. Yau T, Wong H, Chan P, Yao TJ, Pang R, Cheung TT et al. (2012) Phase
II study of bevacizumab and erlotinib in the treatment of advanced
hepatocellular carcinoma patients with sorafenib-refractory disease.
Invest New Drugs 30:2384–2390.
17. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L
et al. (2003) Small hepatocellular carcinoma in cirrhosis: randomized
comparison of radio-frequency thermal ablation versus percutaneous
ethanol injection. Radiology 228:235–240.
18. Fan ST, Ng IO, Poon RT, Lo CM, Liu CL, Wong J. (1999) Hepatectomy for
hepatocellular carcinoma: the surgeon's role in long-term survival. Arch
Surg 134:1124–1130.
19. Belghiti J, Kianmanesh R. (2005) Surgical treatment of hepatocellular
carcinoma. HPB 7:42–49.
20. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A.
(2012) Recommendations for liver transplantation for hepatocellular car-
cinoma: an international consensus conference report. Lancet Oncol
13:e11–e22.
21. Belghiti J, Carr BI, Greig PD, Lencioni R, Poon RT. (2008) Treatment
before liver transplantation for HCC. Ann Surg Oncol 15:993–1000.
22. Lo CM, Fan ST, Liu CL, Chan SC, Ng IOL, Wong J. (2007) Living donor
versus deceased donor liver transplantation for early irresectable hepa-
tocellular carcinoma. Br J Surg 94:78–86.
23. Llovet JM, Fuster J, Bruix J. (1999) Intention-to-treat analysis of surgical
treatment for early hepatocellular carcinoma: resection versus transplan-
tation. Hepatology 30:1434–1440.
24. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS.
(1999) Small hepatocellular carcinoma: treatment with radio-frequency
ablation versus ethanol injection. Radiology 210:655–661.
25. Francica G, Marone G. (1999) Ultrasound-guided percutaneous treat-
ment of hepatocellular carcinoma by radiofrequency hyperthermia with a
‘cooled-tip needle’. A preliminary clinical experience. Eur J Ultrasound
9:145–153.
26. Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L
et al. (1996) Percutaneous RF interstitial thermal ablation in the treatment
of hepatic cancer. AJR Am J Roentgenol 167:759–768.
27. Dubinsky TJ, Cuevas C, Dighe MK, Kolokythas O, Hwang JH. (2008)
High-intensity focused ultrasound: current potential and oncologic appli-
cations. Am J Roentgenol 190:191–199.
28. Feng W, Wang ZB, Chen WZ, Hui Z, Jin B, Zou JZ et al. (2004) Extracor-
poreal high intensity focused ultrasound ablation in the treatment of
patients with large hepatocellular carcinoma. Ann Surg Oncol 11:1061–
1069.
29. Leslie TA, Kennedy JE, Illing RO, Ter Haar GR, Wili F, Phillips RR et al.
(2008) High-intensity focused ultrasound ablation of liver tumours: can
radiological assessment predict the histological response? Br J Radiol
81:564–571.
30. Kennedy JE, Wu F, ter Haar GR, Gleeson FV, Phillips RR, Middleton MR
et al. (2004) High-intensity focused ultrasound for the treatment of liver
tumours. Ultrasonics 42:931–935.
31. Wu CC, Chen WS, Ho MC, Huang KW, Chen CN, Yen JY et al. (2008)
Minimizing abdominal wall damage during high-intensity focused ultra-
sound ablation by inducing artificial ascites. J Acoust Soc Am 124:674–
679.
32. Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G et al. (2002)
Complications of radiofrequency coagulation of liver tumours. Br J Surg
89:1206–1222.
33. Curley SA, Marra P, Beaty K, Ellis LM, Vauthey JN, Abdalla EK et al.
(2004) Early and late complications after radiofrequency ablation of
malignant liver tumors in 608 patients. Ann Surg 239:450–458.
34. Chan AC, Poon RT, Cheung TT, Chok KS, Chan SC, Fan ST et al. (2012)
Survival analysis of re-resection versus radiofrequency ablation for intra-
hepatic recurrence after hepatectomy for hepatocellular carcinoma.
World J Surg 36:151–156.
35. Cheung TT, Poon RT, Yau T, Tsang DS, Lo CM, Fan ST. (2011) High-
intensity focused ultrasound as a treatment for colorectal liver metastasis
in difficult position. Int J Colorectal Dis 27:987–988.
36. Li JJ, Gu MF, Luo GY, Liu LZ, Zhang R, Xu GL. (2009) Complications of
High Intensity Focused Ultrasound for Patients with Hepatocellular Car-
cinoma. Technol Cancer Res Treat 8:217–224.
HPB 573
HPB 2013, 15, 567–573 © 2012 International Hepato-Pancreato-Biliary Association
